PT-141 for women is FDA-approved as Vyleesi (bremelanotide) for hypoactive sexual desire disorder (HSDD) in premenopausal women — a low sex drive that causes personal distress and isn't explained by another condition. Here's what our clinical team at TelosRX hears most.
Low libido is common. It's also genuinely undertreated. PT-141 has FDA approval for a specific indication, a clear mechanism, and real clinical trial data behind it — but most of the questions people ask aren't answered on the drug label. Here are the ones our review team sees most often.
What Is PT-141 and How Does It Work for Women?
PT-141 is the research name for bremelanotide, sold commercially as Vyleesi. It's a synthetic melanocortin receptor agonist — it binds to MC3R and MC4R receptors in the brain that regulate sexual response.
Unlike PDE5 inhibitors (sildenafil, tadalafil), which work by increasing blood flow to genital tissue, PT-141 acts centrally in the brain. It increases sexual desire at the level of the hypothalamus, not through vascular mechanics. That distinction matters: PT-141 can increase desire even when physical arousal isn't the primary issue.
Phase 3 trial data published in PMC (2019) found that premenopausal women with HSDD who received bremelanotide showed statistically significant increases in sexual desire and decreases in distress related to low desire compared with placebo after 24 weeks.
Is PT-141 FDA-Approved for Women?
Yes — for a specific group. The FDA-approved Vyleesi (bremelanotide 1.75 mg injection) is indicated for premenopausal women with acquired, generalized HSDD.
"Acquired" means the low desire developed at some point — it wasn't always there. "Generalized" means it occurs across all types of stimulation, situations, and partners, not just in specific contexts. The label specifically notes it should not be used in postmenopausal women or in men.
Compounded PT-141 is a different category: it is not FDA-approved, and is subject to provider evaluation and federal compounding regulations before dispensing.
What Is HSDD and Do I Qualify?
Hypoactive sexual desire disorder (HSDD) is diagnosed when a person has persistently low sexual desire that causes personal distress — and the distress isn't explained by a medical condition, mental health issue, relationship problem, or a medication side effect.
It's more common than most people realize. Studies suggest HSDD affects roughly 10% of women in premenopausal years. Many go undiagnosed simply because they don't raise it with a provider.
If you think low desire is bothering you, the first step is an evaluation by a licensed provider — not a self-diagnosis. Subject to medical approval, a provider can determine whether HSDD criteria apply and whether PT-141 is appropriate for your situation.
How Is PT-141 Administered and When Does It Work?
The FDA-approved formulation is a subcutaneous injection — given in the abdomen or thigh — 45 minutes before anticipated sexual activity. Onset is 30 to 60 minutes. The label limits use to no more than one dose in 24 hours and no more than 8 doses per month.
Compounded PT-141 also commonly comes as a subcutaneous injection or, in some formulations, a nasal spray (though the nasal formulation doesn't have the same approval pathway as Vyleesi). Any protocol should be established by a licensed provider — not sourced informally.
What Are the Side Effects?
The most common side effects across phase 2b and 3 trials were:
- Nausea — occurring in 22–40% of users, often within the first hour
- Flushing — facial and upper-body warmth in 14–20%
- Headache — in 9–14% of participants
- Injection site reactions — redness, discomfort
- Skin hyperpigmentation — particularly on the face, gums, or breasts with repeated use, more pronounced in people with darker skin
Bremelanotide is contraindicated in people with uncontrolled hypertension or cardiovascular disease. It can cause a transient increase in blood pressure that resolves within 12 hours. Always disclose your full cardiovascular history to your provider before starting.
PT-141 vs Other Sexual Health Approaches: A Quick Comparison
| Approach | Mechanism | FDA Status | Who It's For | Timing |
|---|---|---|---|---|
| PT-141 (Vyleesi) | Central CNS — MC3R/MC4R agonist | FDA-approved (premenopausal women, HSDD) | Premenopausal women with HSDD | 45 min before activity |
| Addyi (flibanserin) | Serotonin/dopamine modulator | FDA-approved (HSDD) | Premenopausal women; daily oral | Daily pill; alcohol restriction |
| Compounded PT-141 | Same mechanism as Vyleesi | Not FDA-approved | Provider-evaluated; off-label | Varies by formulation |
| Kisspeptin | Hypothalamic hormone signaling | Not FDA-approved | Under research; off-label | Varies |
| Testosterone therapy (off-label in women) | Androgenic; libido support | Not FDA-approved for women | Provider-evaluated only | Topical or injectable |
For a deeper look at peptide options for libido research, read our peptides for libido guide. And if you're exploring related research on sexual health peptides, see our Kisspeptin research overview.
Can Women Access PT-141 Through Asynchronous Telehealth?
Yes — through a licensed telehealth service like TelosRX, subject to provider evaluation. TelosRX operates as an asynchronous platform: you complete a detailed health intake that a licensed provider reviews at their discretion. No scheduled calls, no waiting rooms.
If the evaluation supports it, a prescription is issued and a compounded formulation is dispensed through our LegitScript-certified process. Approval is not guaranteed — it's subject to medical approval by a licensed provider. If PT-141 isn't appropriate for your situation, the provider will note why.
Start your private evaluation at TelosRX.
Frequently Asked Questions
How long does PT-141 take to work in women?
PT-141 (as Vyleesi) typically begins working within 30 to 60 minutes of injection. The label recommends injecting 45 minutes before anticipated sexual activity. Effects are usually noticed within that window. The duration of effect varies by individual; most data tracks outcomes over the several hours following administration.
Can PT-141 be used by women after menopause?
The FDA-approved indication is specifically for premenopausal women. Postmenopausal use is off-label. Some providers prescribe PT-141 off-label for postmenopausal women, but that requires careful provider judgment about cardiovascular risk, hormone context, and benefit-risk balance. An evaluation by a licensed provider is required.
Does PT-141 increase estrogen or affect hormones?
No. PT-141 does not act on estrogen, progesterone, or reproductive hormone pathways. It acts on melanocortin receptors in the brain. Its effect is on desire and arousal signals, not hormonal balance. It won't raise or lower estrogen levels.
What's the difference between Vyleesi and compounded PT-141?
Vyleesi is the FDA-approved brand at a fixed 1.75 mg dose, manufactured under FDA oversight. Compounded PT-141 is prepared under federal compounding regulations, is not FDA-approved, and may come in different doses or formulations. Both require a valid prescription from a licensed provider.
Are there drug interactions I should know about?
Bremelanotide can interact with naltrexone. It should not be used in people with uncontrolled hypertension or known cardiovascular disease. Always disclose all medications and conditions during your provider intake. Your prescribing provider will screen for interactions as part of evaluation.
How many times per month can women use PT-141?
Per the Vyleesi label: no more than one dose per 24-hour period, and no more than 8 doses per month. Exceeding this frequency increases risk of side effects, particularly skin hyperpigmentation and cardiovascular strain. Follow your provider's specific instructions, which may be more conservative.
Is PT-141 the same as Kisspeptin for libido?
No. PT-141 (bremelanotide) and Kisspeptin are different peptides with different mechanisms. PT-141 acts on MC3R/MC4R receptors. Kisspeptin acts on the hypothalamic-pituitary axis and influences reproductive hormone signaling. Both are under research for sexual health applications but should not be conflated.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.